Search for European Projects

Over 40 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Towards enduring mouse resources and services advancing research into human health and disease (INFRAFRONTIER2020)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society. The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is st ...
Read Project

 33

 FINISHED 

iABC Programme (IABC PROGRAMME)

Start date: Aug 1, 2015, End date: Jul 31, 2020,

Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomon ...
Read Project

 21

 FINISHED 

HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sjögren’s Syndrome (pSS) towards improved stratification, treatment and health policy making (HarmonicSS)

Start date: Jan 1, 2017, End date: Jun 30, 2020,

HarmonicSS vision is to create an International Network and Alliance of partners and cohorts, entrusted with the mission of addressing the unmet needs in primary Sjogren Syndrome; working together to create and maintain a platform with open standards and tools, designed to enable secure storage, governance, analytics, access control and controlled sharing of information at multiple levels along wi ...
Read Project

 39

 FINISHED 

Personalized Nanomedicines for Leukemia Patients (PNANOMED)

Start date: Jul 1, 2015, End date: Jun 30, 2020,

Acute myeloid leukemia (AML) remains a devastating disease, while progress in genetic characterization and nanomedical approaches promise a new era of individualized treatments. To prioritize genetic aberrations in AML for therapeutic targeting and to develop a pipeline for personalized nanomedicines I will i) establish a biobank of transplantable primary human AML xenotransplants, ii) fully chara ...
Read Project

 1

 FINISHED 

Exploring selected long non-coding RNAs as diagnostics and therapeutic targets for heart failure (LONGHEART)

Start date: Jun 1, 2015, End date: May 31, 2020,

Despite clinical advances, diseases of the cardiovascular system are the most common cause of morbidity and mortality in the EU with currently 50 million people suffering from heart failure. These important challenges call for a better understanding of underlying mechanisms to enable development of innovative, effective diagnostic and therapeutic strategies for heart failure. Cardiac stress such a ...
Read Project

 1

 FINISHED 

Training network providing cutting-EDGE knowlEDGE on Herpes Virology and Immunology (EDGE)

Start date: May 1, 2016, End date: Apr 30, 2020,

Herpesviruses are widely spread, and cause life-long infections. Most individuals carry multiple herpesviruses, which can cause severe diseases, especially in children, immunocompromised individuals, and elderly. There are currently no safe vaccines against herpesvirus infections and current treatments are not satisfactory. With new insights into the molecular basis for diseases caused by immunode ...
Read Project

 9

 FINISHED 

Synergy-based Open-source Foundations and Technologies for Prosthetics and RehabilitatiOn (SoftPro)

Start date: Mar 1, 2016, End date: Feb 29, 2020,

Although much has been done for developing technologies to bear upon problems of individuals with sensorimotor impairments, the impact of robotic aids on people with real needs in the real world is still very limited. Our main goal is to increase the cumulative benefits of assistive robotic technologies to society by enhancing their effectiveness AND the number of beneficiaries. The challenge is ...
Read Project

 13

 FINISHED 

DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) (SCIDNET)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for ...
Read Project

 13

 FINISHED 

Tools and TECHNOlogies for Breakthrough in hEArt Therapies (TECHNOBEAT)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Cardiovascular diseases including myocardial infarction (MI), which entails the irreversible loss of heart muscle tissue, constitute a major socio-economic burden in global healthcare. With whole organ transplantation as the only treatment option for end-stage heart failure, MI patients could particularly benefit from advanced cell therapies aimed at the functional reconstitution of damaged hearts ...
Read Project

 8

 FINISHED 

Development and disease of the renal tract (RENALTRACT)

Start date: Jun 1, 2015, End date: May 31, 2019,

The renal tract (kidneys, the ureters, bladder) is a complex organ system crucial for maintaining the body homeostasis. This organ system arises from different precursor pools through a complex program of patterning, differentiation and morphogenesis in embryonic development. Alteration of this program leads to renal tract malformations (RTM) that are incompatible with a healthy life. While some o ...
Read Project

 8

 FINISHED 

Aortic Valve Replacement using Individualised Regenerative Allografts: Bridging the Therapeutic Gap (ARISE)

Start date: Jan 1, 2015, End date: Mar 31, 2019,

65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. In affected patients, mortality without AVR is extremely high and 50 % die within 2 years. Current AVR options are, however, limited for young patients - especially female patients - and those unwilling to accept life-long medical anticoagulation with its inherent risks. ...
Read Project

 9

 FINISHED 

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases (PRECISESADS)

Start date: Feb 1, 2014, End date: Jan 31, 2019,

We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therape ...
Read Project

 30

 FINISHED 

Heart OMics in AGEing (HOMAGE)

Start date: Feb 1, 2013, End date: Jan 31, 2019,

As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Read Project

 22

 FINISHED 

Targets and biomarkers for antiepileptogenesis (EPITARGET)

Start date: Nov 1, 2013, End date: Oct 31, 2018,

Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a comb ...
Read Project

 20

 FINISHED 

Dobutamine for NEOnatal CIRCulatory failure defined by novel biomarkers (NEO-CIRC)

Start date: Oct 1, 2011, End date: Sep 30, 2018,

Dobutamine and adrenaline are widely used as second line therapy for systemic hypotension in infants. Dopamine is currently the most widely used first line drug. In neonates, sustained hypotension may, and impaired organ perfusion will, cause brain injury and poor neurodevelopmental outcomes. All three catecholamines are currently used off-label and have different modes of action which may result ...
Read Project

 20

 FINISHED 

Higher education student and staff mobility project

Start date: Jun 1, 2016, End date: May 31, 2018,

This is a higher education student and staff mobility project, please consult the website of the organisation to obtain additional details.
Read Project

 1

 FINISHED 

Europa Mobilität in der Ausbildung mit Erasmus über Bildungsakademie Pflege MHH

Start date: Jun 1, 2016, End date: May 31, 2018,

The educational academy Nursing (BAP) is an autonomous vocational training´s department in the framework of the training academy of the Medical University Hanover, traditionally called MHH. The nursing school trains 200 students, the school for OTA/ATA 150. The MHH has in addition another 257 apprenticeships in varied health care professions. We have achieved till 2014 to send over 100 students, i ...
Read Project

 5

 FINISHED 

Safety CaUsation, Benefits and Efficiency (SafetyCube)

Start date: May 1, 2015, End date: Apr 30, 2018,

The objective of SafetyCube is to develop an innovative road safety Decision Support System (DSS) that will enable policy-makers and stakeholders to select and implement the most appropriate strategies, measures and cost-effective approaches to reduce casualties of all road user types and all severities.At the core of the project will be a novel and comprehensive analysis of accident causation fac ...
Read Project

 18

 FINISHED 

Immune and Neuromodulation Mediated by Alphaherpesviruses (INMA)

Start date: Apr 1, 2014, End date: Mar 31, 2018,

Despite the advances against infectious diseases, morbidity and mortality still pose a very high social and economic impact. Viruses have developed a plethora of strategies to modulate the host. The main goal of my research is to investigate these strategies in order to understand viral immunomodulation, neuromodulation and pathogenesis. This will permit us to develop better intervention approache ...
Read Project

 1

 FINISHED 

Lymph node homing of immune cells via afferent lymphatics – mechanisms and immune response (LYMPHATICS-HOMING)

Start date: Apr 1, 2013, End date: Mar 31, 2018,

"The continuous migration of immune cells to lymph nodes (LN) is of utmost importance for the induction of both protective immunity as well as immunological tolerance. Despite this pivotal role, little is known regarding migration paths and the molecular cues regulating homing of immune cells that arrive via afferent lymphatic vessels to LN. This conspicuous lack of knowledge is primarily due to p ...
Read Project

 1

 FINISHED 

Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN)

Start date: Mar 1, 2013, End date: Feb 28, 2018,

In renal allograft recipients, 10-year graft survival has not improved over the past decades. Histological examination of graft biopsies has long been the gold standard to confirm graft injuries, but biopsies are invasive and histological grading is not very robust. There is thus a need for robust, non-invasive methods to predict and diagnose acute and chronic graft lesions, to improve patient tre ...
Read Project

 13

 FINISHED 

Parasite glycobiology and anti-parasitic strategies (GLYCOPAR)

Start date: Dec 1, 2013, End date: Nov 30, 2017,

"Protozoan parasites and helminths are the cause of some of the most devastating diseases worldwide and a major effort is needed to be able to control or eliminate these diseases. Glycoconjugates are abundant and ubiquitous on the surface of many parasites and they are frequently involved in their survival strategies by forming a protective barrier against host defences. A common feature of the pa ...
Read Project

 13

 FINISHED 

The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction (BAMI)

Start date: Nov 1, 2011, End date: Oct 31, 2017,

Although the long term prognosis of patients suffering acute myocardial infarction (AMI) has improved since the introduction of reperfusion therapies and primary angioplasty, the 1 year mortality of patients with AMI and resultant left ventricular systolic dysfunction (LVSD) is still as high as 13%. A major reason for the high morbidity and mortality is that the heart has an inadequate regenerativ ...
Read Project

 23

 FINISHED 

novel bioreactor Platform for reprOducible, Scalable ExpansIonand cardiac DifferentiatiON of hiPSC in suspension culture (POSEIDON)

Start date: Oct 1, 2015, End date: Sep 30, 2017,

Human induced pluripotent stem cells (hiPSCs) have the potential to revolutionize biomedical sciences, however the standardised mass production, indispensable for their industrial and therapeutic use, is still a major challenge. Impeller stirred-tank bioreactors, currently used for hiPSC bioprocessing, impose detrimental stresses on cultured hiPSCs, resulting in heterogeneity of cells and cell-agg ...
Read Project

 1

 FINISHED 

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Read Project

 38

 FINISHED 

Advances in Small Trials dEsign for Regulatory Innovation and eXcellence (ASTERIX)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

"ASTERIX will contribute towards the expected impact listed in the work program by delivering validated innovative statistical design methodologies for cost efficient clinical trials deriving reliable results from trials in small population groups, especially focusing on rare diseases. It directly addresses the rights of the estimated 30 million European patients suffering from rare diseases to th ...
Read Project

 7

 FINISHED 

Innovation in teaching, training and dissemination of virology

Start date: Sep 1, 2014, End date: Aug 31, 2017,

Like viruses themselves, the scientific discipline of Virology has evolved from the study of viruses, to overlap and intertwine with many other scientific disciplines, both traditional and contemporary. As these developments into new areas of science such as gene therapy in treating cancers, reverse genetics in biotechnological assay development and nanotechnology in vaccine design continue to gr ...
Read Project

 8

 FINISHED 

Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)

Start date: Sep 1, 2013, End date: Aug 31, 2017,

The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the p ...
Read Project

 11

 FINISHED 

Quantitative Imaging of Liver Fibrosis and Fibrogenesis (LiverFibrosisImaging)

Start date: Aug 1, 2012, End date: Jul 31, 2017,

Chronic liver disease can progress to cirrhosis, with death due to liver failure and cancer. Cirrhosis prevalence in the EU is 0.5%-1%. However, development of therapies that prevent progression to cirrhosis is hampered by the lack of a sensitive, non-invasive method to quantify fibrosis or fibrosis progression (fibrogenesis). Liver biopsy 1) is risky, 2) shows high sampling variability, and 3) is ...
Read Project

 3

 FINISHED 

Higher education student and staff mobility project

Start date: Jun 1, 2015, End date: May 31, 2017,

This is a higher education student and staff mobility project, please consult the website of the organisation to obtain additional details.
Read Project

 1

 FINISHED 

Europa Mobilität in der Ausbildung mit Erasmus über Bildungsakademie Pflege MHH

Start date: Jun 1, 2015, End date: May 31, 2017,

The educational academy Nursing (BAP) is an autonomous vocational training´s department in the framework of the training academy of the Medical University Hanover, traditionally called MHH. The nursing school trains 200 students, the school for OTA/ATA 150. The MHH has in addition another 257 apprenticeships in varied health care professions. . Since 2006 we have send over 100 students, in their ...
Read Project

 3

 FINISHED 

Erasmus+ Auslandspraktikum

Start date: Jun 1, 2015, End date: May 31, 2017,

For almost 15 years, the Educational Center for Health care of the TILAK GmbH has taken part in the exchange project "Leonardo-da-Vinci". The available programme is now the first among Erasmus+. The internship abroad has developed itself into a steady part of the educational offer. Starting in Autumn 2017, the education for health care and nursing will be an official institution (College). And ...
Read Project

 16

 FINISHED 

European Multicentre Tics in Children Studies (EMTICS)

Start date: Dec 1, 2011, End date: May 31, 2017,

This project will undertake pre-clinical and cohort studies that address susceptibility factors for paediatric and adolescent tic disorders, with a particular focus on comorbid obsessive-compulsive symptomatology, from clinical, epidemiological, genetic, microbiological and immunological angles. EMTICS aims to elucidate the complex aetiology of the onset and clinical course of chronic tic disorder ...
Read Project

 33

 FINISHED 

New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier (TRANS-INT)

Start date: May 1, 2012, End date: Apr 30, 2017,

Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improveme ...
Read Project

 20

 FINISHED 

Improving the organisation of maternal health service delivery, and optimising childbirth, by increasing vaginal birth after caesarean section (VBAC) through enhanced women-centred care (OPTIBIRTH)

Start date: Sep 1, 2012, End date: Feb 28, 2017,

Optimal, healthy pregnancy followed by normal birth is the ideal. Caesarean section (CS) doubles the risk of mortality and morbidity (hysterectomy, blood transfusion), and increases the risk of postnatal infection by 5, compared with vaginal birth (WHO Global Survey on Maternal and Perinatal Health). The European Perinatal Health Report (2008) notes “widespread concern” over rising CS rates, which ...
Read Project

 11

 FINISHED 

Towards Tissue Engineering Solutions for Cardiovascular Surgery (TECAS)

Start date: Jan 1, 2013, End date: Dec 31, 2016,

"The aim of the TECAS ITN is to integrate the major European contributors in the field of cardiovascular tissue engineering (TE) and regenerative medicine (RM), to generate a coherent framework of expertise which will facilitate the training and career development of early stage researchers (ESRs) in the field. In particular, the intention of this ITN is to focus on the clinical needs of cardiac v ...
Read Project

 7

 FINISHED 

European clinical study for the application of regenerative heart valves (ESPOIR)

Start date: Jan 1, 2012, End date: Dec 31, 2016,

Acquired and congenital heart disease can necessitate heart valve replacement. However, current heart valve substitutes are not considered ideal as they need anticoagulation, bearing the risk of bleeding when manufactured from non-organic material, or they degenerate when they derive from animals or human tissue donators (homografts) thereby leading to frequent reoperation especially in the young ...
Read Project

 15

 FINISHED 

Orphans Unite: chILD better together – European Management Platform for Childhood Interstitial Lung Diseases (CHILD-EU)

Start date: Dec 1, 2012, End date: Nov 30, 2016,

Children with diffuse lung disease, also called childhood interstitial lung diseases (chILD), may have one of more than 200 entities, the biggest group of respiratory orphan lung diseases. Frequently undiagnosed because of lack of awareness or complex differential diagnosis, they lead to much morbidity, mortality (about 15%) and psychosocial stress for the families. Current lack of evidence based ...
Read Project

 10

 FINISHED 

Improving HSCT By Validation Of Biomarkers & Development Of Novel Cellular Therapies (CELLEUROPE)

Start date: Oct 1, 2012, End date: Sep 30, 2016,

Novel transplant regimens are currently being developed to improve beneficial GvL effects and reduce GvHD and infections via several new forms of cellular therapies. This newly emerging supra-disciplinary field of cellular therapy and regenerative medicine is also being used to improve outcomes in autoimmune disease (such as Rheumatoid Arthritis) and cancers. The goal of this research programme is ...
Read Project

 13

 FINISHED 

ACTive Implant for Optoacoustic Natural sound enhancement (ACTION)

Start date: Oct 1, 2013, End date: Sep 30, 2016,

The ACTION project builds on the recent discovery that relatively low levels of pulsed infrared laser light are capable of triggering activity in hair cells of the partially hearing (hearing impaired) cochlea and vestibule. So far the excessively large volume of optical fibre systems and external light sources used for animal studies prevented the practical use of this discovery for long term anim ...
Read Project

 7